Gill Dalvir, Gadela Naga Vaishnavi, Azmeen Ayesha, Jaiswal Abhishek
Hartford HealthCare Heart and Vascular Institute, Hartford Hospital, Hartford, Connecticut.
Internal Medicine, University of Connecticut, Farmington, Connecticut.
Proc (Bayl Univ Med Cent). 2020 Oct 16;34(1):169-171. doi: 10.1080/08998280.2020.1830332.
Worsening symptoms and fluid overload are the hallmarks of heart failure (HF) decompensation, and fluid removal is central to improvement. Despite high-dose loop diuretics, patients with decompensated HF may develop suboptimal diuresis/diuretic resistance. Sequential nephron blockade with a combination of loop and thiazide/thiazide-like diuretics may be insufficient, resulting in poor outcomes. We present a case wherein urine output improved significantly with acetazolamide. Although the diuretic capacity of acetazolamide is weak on its own, it might be efficient in aiding the efficacy of loop diuretics. We discuss the pathophysiological basis and evidence behind its potential role in diuretic resistance. Drawing from current understanding, we propose a stepwise approach to diuresis in such patients.
症状恶化和液体超负荷是心力衰竭(HF)失代偿的标志,而液体清除是改善病情的关键。尽管使用了大剂量的袢利尿剂,但失代偿性HF患者可能会出现利尿效果不佳/利尿剂抵抗。联合使用袢利尿剂和噻嗪类/噻嗪样利尿剂进行序贯肾单位阻滞可能并不充分,导致预后不良。我们报告一例使用乙酰唑胺后尿量显著改善的病例。虽然乙酰唑胺本身的利尿能力较弱,但它可能有助于增强袢利尿剂的疗效。我们讨论了其在利尿剂抵抗中潜在作用的病理生理基础和证据。基于目前的认识,我们提出了对此类患者进行利尿治疗的逐步方法。